Monte Rosa Therapeutics financials
$11.74+0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $123.7M | $75.6M | $0.00 | $0.00 | — |
| Gross profit | $123.7M | $75.6M | $0.00 | $0.00 | — |
| Gross margin | 100.0% | 100.0% | — | — | — |
| Operating income | -$54.2M | -$81.1M | -$143.3M | -$112.4M | -$72.9M |
| Net income | -$38.6M | -$72.7M | -$135.4M | -$108.5M | -$74.0M |
| Net margin | −31.2% | −96.1% | — | — | — |
| Diluted EPS | $-0.46 | $-0.98 | $-2.63 | $-2.30 | $-2.96 |
| EBITDA | -$45.9M | -$73.0M | -$137.1M | -$108.6M | -$70.8M |
| Operating cash flow | -$22.8M | $42.0M | -$43.8M | -$92.5M | -$59.4M |
| Free cash flow | -$27.5M | $38.0M | -$62.8M | -$105.4M | -$69.1M |
| Diluted shares | 83.1M | 73.9M | 51.4M | 47.2M | 25.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $129.9M | $224.3M | $128.1M | $54.9M | $346.1M |
| Short-term investments | $247.2M | $147.9M | $104.3M | $207.9M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $448.7M | $438.7M | $303.8M | $342.4M | $366.3M |
| Total liabilities | $215.6M | $215.8M | $124.5M | $71.0M | $18.8M |
| Shareholders' equity | $233.1M | $222.9M | $179.3M | $271.4M | $347.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology